Resource Type

Journal Article 72

Conference Videos 2

Year

2023 5

2022 4

2021 11

2020 6

2019 5

2018 3

2017 2

2016 4

2015 4

2014 7

2013 3

2012 4

2011 3

2010 2

2009 1

2008 1

2007 1

2006 1

1999 1

open ︾

Keywords

COVID-19 5

SARS-CoV-2 4

monoclonal antibody 4

antibody 3

cancer 3

Antibody response 2

DNA 2

Efficacy 2

Monoclonal antibody 2

PD-1 2

PD-L1 2

pathogenesis 2

polyclonal antibody 2

therapeutic 2

therapeutic strategy 2

therapeutic target 2

-acetylglucosamine 1

21) 1

Nsp9 1

open ︾

Search scope:

排序： Display mode:

Modified Therapeutic Antibodies: Improving Efficacy Review

Ji-Min Dai, Xue-Qin Zhang, Jing-Yao Dai, Xiang-Min Yang, Zhi-Nan Chen

Engineering 2021, Volume 7, Issue 11,   Pages 1529-1540 doi: 10.1016/j.eng.2020.06.030

Abstract:

The prosperity of the biotherapeutics market reflects the feasibility and effectiveness of therapeuticsuch as impeded binding, reduced effector functions, and frequent adverse reactions, modifications of therapeuticof crystallizable domain (Fc) amino acid alterations; ③ cross-isotype or cross-subclass exchanges; ④ antibodyThis review recapitulates the international progress that has been achieved with modified therapeutic

Keywords： Therapeutic antibody     Modification     Efficacy     Antigen     Antibody–drug conjugate     Bispecific antibody    

HTML PDF Collect

CD47 blockade improves the therapeutic effect of osimertinib in non-small cell lung cancer

Frontiers of Medicine 2023, Volume 17, Issue 1,   Pages 105-118 doi: 10.1007/s11684-022-0934-1

Abstract: The combination treatment of OSI and the anti-CD47 antibody exhibited dramatically increasing phagocytosisin HCC827 and NCI-H1975 cells, which highly relied on the antibody-dependent cellular phagocytosis effectMeanwhile, combining the anti-CD47 antibody significantly augmented the anticancer effect of OSI in HCC827the multidimensional regulation by OSI and encourage the further exploration of combining anti-CD47 antibody

Keywords： osimertinib     anti-CD47 antibody     combination strategy     ADCP     EGFR    

HTML PDF Collect

Vaccine therapies for chronic hepatitis B: can we go further?

Yumei Wen, Xuanyi Wang, Bin Wang, Zhenhong Yuan

Frontiers of Medicine 2014, Volume 8, Issue 1,   Pages 17-23 doi: 10.1007/s11684-014-0313-7

Abstract: In addition to the recent progress in antiviral treatment, therapeutic vaccination is a promising newhepatitis B patients, this paper presents the peptide and protein-based, DNA-based, cell-based, and antigen-antibody-basedtherapeutic vaccines, which have undergone clinical trials.The advantages, disadvantages, and future perspectives for these therapeutic vaccines are discussed.

Keywords： chronic hepatitis B     therapeutic     antigen-antibody complexes     DNA     vaccine    

HTML PDF Collect

Neutralizing monoclonal antibodies present new prospects to treat SARS-CoV-2 infections

Rongtao Lai, Tianhui Zhou, Xiaogang Xiang, Jie Lu, Haiguang Xin, Qing Xie

Frontiers of Medicine 2021, Volume 15, Issue 4,   Pages 644-648 doi: 10.1007/s11684-021-0847-4

Abstract: Thus, new therapeutic strategies and effective vaccines are urgently needed to cope with this severeThe development of a broadly neutralizing antibody against severe acute respiratory syndrome coronavirusA single monoclonal antibody (mAb) treatment is prone to selective pressure due to increased possibilityIn addition, the antibody-dependent enhancement effect is a potential risk of enhancing the viral infectionor more antibodies that recognize different regions of the viral surface may be the most effective therapeutic

Keywords： neutralizing antibody     antibody cocktail     SARS-CoV-2     COVID-19     therapeutic strategy    

HTML PDF Collect

Experimental Studies on Recombinant Hepatitis B Immunogenic Complex Therapeutic Vaccine (YIC)

Wenyu mei,He Lifang,Qu Di,Ma Zhangmei,Yao Xin

Strategic Study of CAE 1999, Volume 1, Issue 1,   Pages 38-42

Abstract:

A therapeutic vaccine composed of HBsAg complexed to anti-HBs (IC) has been developed for viral hepatitisAfter being ingested, the antigen complexed to antibody could be more effectively processed and presentedimmune response in host has also been shown by comparing anti-HBs titer in mice immunized with antigen-antibodythe normal responsive counterpart mouse strain (BIO), immunization with HBsAg induced low titer of antibodyFor human use, a therapeutic vaccine composed of yeast-derived recombinant HBsAg complexed to human high-titer

Keywords： hepatitis B     therapeutic vaccine     antigen-antibody complex     immune responses    

HTML PDF Collect

Circulating microRNAs in cardiovascular diseases: from biomarkers to therapeutic targets

Feng Wang,Chen Chen,Daowen Wang

Frontiers of Medicine 2014, Volume 8, Issue 4,   Pages 404-418 doi: 10.1007/s11684-014-0379-2

Abstract: functions of circulating miRNAs in cardiovascular system but also inform the development of miRNAs therapeuticthe potential roles of circulating miRNAs in a variety of cardiovascular diseases from biomarkers to therapeutic

Keywords： microRNA     cardiovascular disease     biomarkers     therapeutic target    

HTML PDF Collect

Brown and beige fat: the metabolic function, induction, and therapeutic potential

Shuwen Qian,Haiyan Huang,Qiqun Tang

Frontiers of Medicine 2015, Volume 9, Issue 2,   Pages 162-172 doi: 10.1007/s11684-015-0382-2

Abstract: induce the development, the activation of brown or beige adipose tissue, which seem to be promising for therapeutic

Keywords： brown adipocyte     beige adipocyte     metabolism     obesity    

HTML PDF Collect

Molecular mechanisms and therapeutic strategies of vulnerable atherosclerotic plaques

Wen-Qiang CHEN MD, Yun ZHANG MD, PhD, FACC,

Frontiers of Medicine 2010, Volume 4, Issue 1,   Pages 36-42 doi: 10.1007/s11684-010-0020-y

Abstract: Vulnerable atherosclerotic plaque rupture leading to thrombosis is the major cause of acute coronary syndrome (ACS). Studies on the pathophysiologic mechanism of both ACS and plaque stabilizing treatment are driving the development of animal models of vulnerable plaque. In our laboratory, we established animal models of plaque rupture and thrombosis in rabbits and mice that are similar to human plaque rupture. Potential mechanisms involved in plaque vulnerability were studied from the inflammation-immunity, proliferation-apoptosis, oxidative stress and biomechanics aspects. Imaging markers and biomarkers were used to detect vulnerable plaques, including high frequency duplex ultrasound, intravascular ultrasound (IVUS), intravascular ultrasound elastography, magnetic resonance imaging (MRI) and inflammatory markers. Effective gene and drug strategies to treat vulnerable plaques were explored.

Keywords： vulnerable plaque     animal models     mechani-sm     detection     treatment    

HTML PDF Collect

Advances in COVID-19: the virus, the pathogenesis, and evidence-based control and therapeutic strategies

Guangbiao Zhou, Saijuan Chen, Zhu Chen

Frontiers of Medicine 2020, Volume 14, Issue 2,   Pages 117-125 doi: 10.1007/s11684-020-0773-x

Abstract: the insights in the virus, the responses of the host cells, the cytokine release syndrome, and the therapeutic

Keywords： COVID-19     SARS-CoV-2     pathogenesis     evidence-based medicine     control and therapeutic strategies    

HTML PDF Collect

BGB-A445, a novel non-ligand-blocking agonistic anti-OX40 antibody, exhibits superior immune activation

Frontiers of Medicine doi: 10.1007/s11684-023-0996-8

Abstract: Here, we discovered that BGB-A445, a non-ligand-competitive agonistic anti-OX40 antibody currently underdose-dependently and significantly depleted regulatory T cells in vitro and in vivo via antibody-dependentdemonstrated robust and dose-dependent antitumor efficacy, whereas the ligand-competitive anti-OX40 antibodyFurthermore, BGB-A445 demonstrated a strong combination antitumor effect with an anti-PD-1 antibody.

Keywords： BGB-A445     OX40     agonistic antibody     OX40L noncompetitive    

HTML PDF Collect

Passive antibody therapy in emerging infectious diseases

Frontiers of Medicine doi: 10.1007/s11684-023-1021-y

Abstract: Antibody therapies encompassing convalescent plasma, hyperimmunoglobulin, and neutralizing monoclonalIn addition, the prospects of applying antibody therapy against VOCs was assessed, offering insights

Keywords： SARS-CoV-2     COVID-19     convalescent plasma     hyperimmunoglobulin     neutralizing monoclonal antibodies    

HTML PDF Collect

Production of a polyclonal antibody to the VP26 nucleocapsid protein of white spot syndrome virus (wssv

Suchera LOYPRASERT-THANANIMIT, Akrapon SALEEDANG, Proespichaya KANATHARANA, Panote THAVARUNGKUL, Wilaiwan CHOTIGEAT

Frontiers of Chemical Science and Engineering 2012, Volume 6, Issue 2,   Pages 216-223 doi: 10.1007/s11705-012-1289-y

Abstract: The objective of this work was to produce a polyclonal antibody against VP26 and use it as a biosensorprotein (rVP26) was produced in (BL21), purified and used for immunizing rabbits to obtain a polyclonal antibody

Keywords： recombinant protein     polyclonal antibody     label-free biosensor     impedance     white spot syndrome virus (WSSV    

HTML PDF Collect

Resistance to receptor tyrosine kinase inhibition in cancer: molecular mechanisms and therapeutic strategies

Peter B. Alexander,Xiao-Fan Wang

Frontiers of Medicine 2015, Volume 9, Issue 2,   Pages 134-138 doi: 10.1007/s11684-015-0396-9

Abstract: of resistance to receptor tyrosine kinase inhibitors, which are the most prevalent class of targeted therapeutic

Keywords： targeted therapy     drug resistance     receptor tyrosine kinases     cancer    

HTML PDF Collect

Growth suppression of colorectal cancer expressing S492R EGFR by monoclonal antibody CH12

Qiongna Dong, Bizhi Shi, Min Zhou, Huiping Gao, Xiaoying Luo, Zonghai Li, Hua Jiang

Frontiers of Medicine 2019, Volume 13, Issue 1,   Pages 83-93 doi: 10.1007/s11684-019-0682-z

Abstract: Recently, treatments using cetuximab, also named C225, an anti-EGFR monoclonal antibody, for CRC haveand S492R EGFR accelerate the growth of CRC cells in vitro and in vivo and monoclonal antibodyFurthermore, mAb CH12 showed significantly stronger growth suppression activities and induced a more potent antibody-dependentThus, mAb CH12 may be a promising therapeutic agent in treating patients with CRC bearing an S492R EGFR

Keywords： S492R EGFR ectodomain mutation     colorectal cancer     mAb CH12     immunnotherapy    

HTML PDF Collect

Triterpenoid inducers of Nrf2 signaling as potential therapeutic agents in sickle cell disease: a review

Amma Owusu-Ansah,Sung Hee Choi,Agne Petrosiute,John J. Letterio,Alex Yee-Chen Huang

Frontiers of Medicine 2015, Volume 9, Issue 1,   Pages 46-56 doi: 10.1007/s11684-015-0375-1

Abstract: important intermediate in these pathophysiological processes and is therefore an important target for therapeuticexpression of anti-oxidant enzymes and is emerging as a protein whose function can be exploited with therapeuticThe article concludes with a perspective on the potential of the various therapeutic interventions to

Keywords： oxidative stress     Nrf2     triterpenoids     sickle cell disease     vaso-occlusion     CDDO-Me    

HTML PDF Collect

Title Author Date Type Operation

Modified Therapeutic Antibodies: Improving Efficacy

Ji-Min Dai, Xue-Qin Zhang, Jing-Yao Dai, Xiang-Min Yang, Zhi-Nan Chen

Journal Article

CD47 blockade improves the therapeutic effect of osimertinib in non-small cell lung cancer

Journal Article

Vaccine therapies for chronic hepatitis B: can we go further?

Yumei Wen, Xuanyi Wang, Bin Wang, Zhenhong Yuan

Journal Article

Neutralizing monoclonal antibodies present new prospects to treat SARS-CoV-2 infections

Rongtao Lai, Tianhui Zhou, Xiaogang Xiang, Jie Lu, Haiguang Xin, Qing Xie

Journal Article

Experimental Studies on Recombinant Hepatitis B Immunogenic Complex Therapeutic Vaccine (YIC)

Wenyu mei,He Lifang,Qu Di,Ma Zhangmei,Yao Xin

Journal Article

Circulating microRNAs in cardiovascular diseases: from biomarkers to therapeutic targets

Feng Wang,Chen Chen,Daowen Wang

Journal Article

Brown and beige fat: the metabolic function, induction, and therapeutic potential

Shuwen Qian,Haiyan Huang,Qiqun Tang

Journal Article

Molecular mechanisms and therapeutic strategies of vulnerable atherosclerotic plaques

Wen-Qiang CHEN MD, Yun ZHANG MD, PhD, FACC,

Journal Article

Advances in COVID-19: the virus, the pathogenesis, and evidence-based control and therapeutic strategies

Guangbiao Zhou, Saijuan Chen, Zhu Chen

Journal Article

BGB-A445, a novel non-ligand-blocking agonistic anti-OX40 antibody, exhibits superior immune activation

Journal Article

Passive antibody therapy in emerging infectious diseases

Journal Article

Production of a polyclonal antibody to the VP26 nucleocapsid protein of white spot syndrome virus (wssv

Suchera LOYPRASERT-THANANIMIT, Akrapon SALEEDANG, Proespichaya KANATHARANA, Panote THAVARUNGKUL, Wilaiwan CHOTIGEAT

Journal Article

Resistance to receptor tyrosine kinase inhibition in cancer: molecular mechanisms and therapeutic strategies

Peter B. Alexander,Xiao-Fan Wang

Journal Article

Growth suppression of colorectal cancer expressing S492R EGFR by monoclonal antibody CH12

Qiongna Dong, Bizhi Shi, Min Zhou, Huiping Gao, Xiaoying Luo, Zonghai Li, Hua Jiang

Journal Article

Triterpenoid inducers of Nrf2 signaling as potential therapeutic agents in sickle cell disease: a review

Amma Owusu-Ansah,Sung Hee Choi,Agne Petrosiute,John J. Letterio,Alex Yee-Chen Huang

Journal Article